NVNO:NASDAQenVVeno Medical Corporation Analysis

NVNO trades at $12.53, hovering just above the computed support of $9.79 and touching its recent resistance of $12.53. The 14‑day RSI of 67 suggests the stock is approaching overbought conditions, while the MACD line sits bullishly above its signal (0.28 vs 0.10). A high computed beta of 2.4 and 30‑day volatility of 64.7% underscore pronounced price swings, compounded by a tiny market cap (~$8.2 M) and decreasing volume, flagging liquidity concerns.
Fundamentally, the company remains pre‑revenue with negative earnings and cash burn, but it holds $28.2 M in cash against minimal debt and a low price‑to‑book of 0.30. Recent news highlights accelerated development of the enVVe System and a projected operating runway into mid‑2027, indicating potential catalyst if the pivotal trial initiates as planned.